Comparative Pharmacology
Head-to-head clinical analysis: ILOTYCIN GLUCEPTATE versus R P MYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILOTYCIN GLUCEPTATE versus R P MYCIN.
ILOTYCIN GLUCEPTATE vs R-P MYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin gluceptate is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
R-P MYCIN is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, specifically at the 23S rRNA of the peptidyl transferase center. This action blocks the translocation step, thereby preventing the elongation of the peptide chain.
Erythromycin gluceptate (Ilotycin Gluceptate) is administered intravenously at a dose of 250-500 mg every 6 hours for adults. Maximum daily dose: 4 g.
Rifampin 600 mg orally once daily or 10 mg/kg intravenously once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in adults with normal renal function; may be prolonged in hepatic impairment (up to 5-6 hours).
Terminal half-life 2-3 hours; prolonged in renal impairment (up to 6-8 hours in anuria).
Primarily hepatic metabolism and biliary excretion; about 10-15% excreted unchanged in urine; some fecal elimination due to biliary excretion.
Renal (60-80% unchanged), biliary/fecal (15-20%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic